- Home
- MOLN vs IPHA Comparison
MOLN vs IPHA Comparison
Compare MOLN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOLN | IPHA |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | Switzerland | France |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.8M | 174.2M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MOLN | IPHA |
|---|---|---|
| Price | $4.33 | $1.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.75 | ★ $5.00 |
| AVG Volume (30 Days) | 2.3K | ★ 21.7K |
| Earning Date | 10-30-2025 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | $1,000.00 | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.36 | $1.47 |
| 52 Week High | $5.91 | $3.51 |
Technical Indicators
Market Signals| Indicator | MOLN | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 42.81 |
| Support Level | $4.13 | $1.85 |
| Resistance Level | $4.57 | $1.91 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 54.03 | 11.63 |
Price Performance
Historical ComparisonAbout MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.